Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms

Cell Death and Disease

Volumn 2, Issue 7, 2011, Pages

  Liu, B ^a,b   Wen, J K ^a   Li, B H ^a   Fang, X M ^a   Wang, J J ^a   Zhang, Y P ^a   Shi, C J ^a   Zhang, D Q ^a   Han, M ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Provincial Hospital of Armed Police   (China)

Author keywords

acetylbritannilactone; apoptosis; breast cancer; cell cycle; cyclooxygenase 2

Indexed keywords

ACETYLBRITANNILACTONE; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PLANT EXTRACT; PROTEIN P21; UNCLASSIFIED DRUG; ACETYLBRITANNILATONE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 2 INHIBITOR; HERBACEOUS AGENT; LACTONE; PROTEIN KINASE B; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CHINESE HERB; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INULA BRITANNICA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; GENETICS; METABOLISM; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUGS, CHINESE HERBAL; FEMALE; G0 PHASE; G1 PHASE; HUMANS; LACTONES; MICE; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 80051483357     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.64     Document Type: Article

References (47)

1. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8: 97-114. (Pubitemid 32641352)
2. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-1009.
3. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelialstromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci USA 2009; 106: 3372-3377.
4. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G et al. Breast cancer and nonsteroidal anti-inflammatory drugs: Prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-6101. (Pubitemid 37187516)
5. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291: 2433-2440. (Pubitemid 38669186)
6. Hinz B, Brune K. Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 2002; 300: 367-375.
7. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140. (Pubitemid 43361545)
8. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-2110. (Pubitemid 36015122)
9. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-2103. (Pubitemid 30225166)
10. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004; 2: 632-642. (Pubitemid 39557666)
11. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)- independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736-747. (Pubitemid 43983297)
12. Kang HK, Lee E, Pyo H, Lim SJ. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 2005; 4: 1358-1363.
13. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: Correlation with suppression of COX-2 synthesis. J Immunol 2004; 173: 2011-2022. (Pubitemid 38971638)
14. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-2744.
15. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738-747.
16. Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005; 11: 6738-6744. (Pubitemid 41339017)
17. Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V et al. A phase 2 pilot trial of lowdose, continuous infusion, or 'metronomic' paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010; 116: 1751-1756.
18. Dogne JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: From light to shadow. Curr Pharm Des 2006; 12: 971-975.
19. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114: 1028-1035. (Pubitemid 44358879)
20. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080. (Pubitemid 40365348)
21. Liu B, Han M, Wen JK. Acetylbritannilactone Inhibits Neointimal Hyperplasia after Balloon Injury of Rat Artery by Suppressing Nuclear Factor-{kappa}B Activation. J Pharmacol Exp Ther 2008; 324: 292-298. (Pubitemid 350294152)
22. Liu YP, Wen JK, Zheng B, Zhang DQ, Han M. Acetylbritannilactone suppresses lipopolysaccharide-induced vascular smooth muscle cell inflammatory response. Eur J Pharmacol 2007; 577: 28-34. (Pubitemid 47632521)
23. Liu B, Han M, Sun RH, Wang JJ, Liu YP, Wen JK. Acetylbritannilactone induces G(1) arrest and apoptosis in vascular smooth muscle cells. Int J Cardiol 2011; 149: 30-38.
24. Bai N, Lai CS, He K, Zhou Z, Zhang L, Quan Z et al. Sesquiterpene lactones from Inula britannica and their cytotoxic and apoptotic effects on human cancer cell lines. J Nat Prod 2006; 69: 531-535. (Pubitemid 43798096)
25. Rafi MM, Bai NS, Chi Tang H, Rosen RT, White E, Perez D et al. A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. Anticancer Res 2005; 25: 313-318. (Pubitemid 40470125)
26. Park EJ, Kim J. Cytotoxic sesquiterpene lactones from Inula britannica. Planta Med 1998; 64: 752-754. (Pubitemid 29021577)
27. Pan MH, Chiou YS, Cheng AC, Bai N, Lo CY, Tan D et al. Involvement of MAPK, Bcl-2 family, cytochrome c, and caspases in induction of apoptosis by 1,6-O,Odiacetylbritannilactone in human leukemia cells. Mol Nutr Food Res 2007; 51: 229-238. (Pubitemid 47083254)
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
29. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 9357-9360. (Pubitemid 28183012)
30. Mehar A, Macanas-Pirard P, Mizokami A, Takahashi Y, Kass GE, Coley HM. The effects of cyclooxygenase-2 expression in prostate cancer cells: Modulation of response to cytotoxic agents. J Pharmacol Exp Ther 2008; 324: 1181-1187. (Pubitemid 351397841)
31. Degner SC, Kemp MQ, Bowden GT, Romagnolo DF. Conjugated linoleic acid attenuates cyclooxygenase-2 transcriptional activity via an anti-AP-1 mechanism in MCF-7 breast cancer cells. J Nutr 2006; 136: 421-427. (Pubitemid 43228296)
32. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996; 56: 5125-5127. (Pubitemid 26383023)
33. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/ TLR9 and promoter regulation. J Immunol 2005; 175: 8242-8252.
34. Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009; 20: 615-620.
35. Canney PA, Machin MA, Curto J. A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer 2006; 42: 2751-2756. (Pubitemid 44584673)
36. Mustafa A, Kruger WD. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res 2008; 14: 4935-4942.
37. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38: 225-242. (Pubitemid 30156623)
38. Cassidy PB, Moos PJ, Kelly RC, Fitzpatrick FA. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: Structure-activity relationships and their implications. Clin Cancer Res 2002; 8: 846-855. (Pubitemid 34742117)
39. Hsueh CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother Pharmacol 2000; 45: 389-396. (Pubitemid 30217163)
40. Flockhart RJ, Diffey BL, Farr PM, Lloyd J, Reynolds NJ. NFAT regulates induction of COX- 2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure. FASEB J 2008; 22: 4218-4227.
41. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004; 101: 591-596. (Pubitemid 38084681)
42. Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE et al. Celecoxib toxicity is cell cycle phase specific. Cancer Res 2007; 67: 3801-3808. (Pubitemid 46762167)
43. Abbas T, Dutta A. p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
44. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003; 4: 425-429. (Pubitemid 38050039)
45. Takada Y, Sethi G, Sung B, Aggarwal BB. Flavopiridol suppresses tumor necrosis factorinduced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Mol Pharmacol 2008; 73: 1549-1557. (Pubitemid 351574844)
46. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ et al. Paclitaxelinduced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2- terminal kinase and Akt. Cancer Res 2006; 66: 212-220. (Pubitemid 43166027)
47. Liu B, Han M, Sun RH, Wang JJ, Zhang YP, Zhang DQ et al. ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation. Breast Cancer Res 2010; 12: R9.